Press Releases

A new approach to CAR T therapy has shown great promise against small cell lung cancer in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.

As the legalization of medicinal and recreational cannabis becomes more common in localities across the country, so does research on its use and effects. Results of an anonymous cancer patient and survivor survey conducted by a team from Roswell Park Comprehensive Cancer Center’s Center for Translational Research on Cannabis and Cancer (CTRCC) will be shared at the American Association for Cancer Research 2023 Annual Meeting in Orlando.

A recent research effort led by Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center, demonstrated that a new chemotherapy combination — trifluridine/tipiracil (FTD/TPI) and oxaliplatin — is well tolerated and has activity among patients with esophageal cancer.

A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center reports benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or tumor anatomy. These findings will be presented by first author Arya Mariam Roy, MBBS, during the American Association for Cancer Research (AACR) annual meeting, continuing through April 19 in Orlando, Florida.

Research from Roswell Park Comprehensive Cancer Center shows that following the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for the diagnosis and treatment of cancer results in better outcomes for patients — but adherence to the guidelines depends on where the patient is diagnosed and treated and what type of cancer is involved.

Roswell Park Comprehensive Cancer Center physician-scientists and researchers will present new research on emerging treatment options and population health at the 2023 annual meeting of the American Association for Cancer Research, taking place in Orlando, Florida, from April 14-19.

Roswell Park Comprehensive Cancer Center is proud to announce the promotion and appointment of three leaders to executive roles overseeing key aspects of research, education and facilities management.

Roswell Park Comprehensive Cancer Center Chief of Colorectal Surgery Steven Nurkin, MD, MS, FACS, is slated to speak at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference, happening March 31-April 2 in Orlando.

Research conducted at Roswell Park Comprehensive Cancer Center shows that the types of T cells circulating in the blood of patients with recurrent ovarian cancer may predict the likelihood that their disease will respond to an anti-PD1 immunotherapy. The findings, which grew out of a phase 2 clinical trial led by Emese Zsiros, MD, PhD, FACOG, Chair and Director of Research, Department of Gynecologic Oncology, will be highlighted at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, March 25-28 in Tampa, Florida.